FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments of consolidated fund	$ 9,637	$ 13,287
Equity investments	9,589	11,650
Level III | Due to DB Med Investors
Level III Financial Liabilities as of September 30, 2020
Balance at December 31, 2019	1,750
Payments	0
Realized and Unrealized Depreciation	(209)
Balance at September 30, 2020	0
Level III | Consolidated Subsidiaries | Due to DB Med Investors
Level III Financial Liabilities as of September 30, 2020
Settlement of liability to DB Med Investors, at fair value	(1,541)
Level III | Consolidated Subsidiaries | Investments
Level III Financial Assets as of September 30, 2020
Balance at December 31, 2019	1,331
Deconsolidation of STRF	(940)
Transfers In or (Out) of Level III	0
Realized and Unrealized Depreciation	(295)
Sale of Level III Assets	(96)
Balance at September 30, 2020	$ 0
Reported Value Measurement | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments		200
Reported Value Measurement | Senior Notes | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets		1,300
Reported Value Measurement | Level I | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity investments		100
Reported Value Measurement | Level III | Senior Notes | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets		1,300
Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets		1,441
Due to DB Med Investors		1,750
Total Liabilities		1,750
Nonrecurring | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments of consolidated fund		1,441
Nonrecurring | Reported Value Measurement | Level I
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets		110
Due to DB Med Investors		0
Total Liabilities		0
Nonrecurring | Reported Value Measurement | Level I | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments of consolidated fund		110
Nonrecurring | Reported Value Measurement | Level II
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets		0
Due to DB Med Investors		0
Total Liabilities		0
Nonrecurring | Reported Value Measurement | Level II | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments of consolidated fund		0
Nonrecurring | Reported Value Measurement | Level III
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total Assets		1,331
Due to DB Med Investors		1,750
Total Liabilities		1,750
Nonrecurring | Reported Value Measurement | Level III | Consolidated Subsidiaries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments of consolidated fund		$ 1,331